celltrion vaccine baxter
Scope
Date
~
-
Bio & Pharma
Biosimilar giant Celltrion to transform into drug developer
South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...
Mar 29, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion founder returns to management with M&A pledge
South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...
Mar 28, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion eyes Baxter's arm as it gears up for M&As
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma wins $44 mn flu vaccine order from WHO agency
South Korea's pharmaceutical firm GC Biopharma Corp. said on Monday that it has won a $44.3 million (57.9 billion won) order for flu vaccines in a d...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Genuv sign agreement for antibody joint R&D
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma's licensed flu vaccine gets approval in Taiwan
South Korea's pharmaceutical firm GC Biopharma Corp. announced on Monday that its quadrivalent flu vaccine has received marketing approval from the ...
Mar 13, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma to develop mRNA flu vaccine with Canadian pharma
South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...
Mar 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Phase 3 clinical plan for SK Bioscience's booster shot approved in Colombia
SK Bioscience Co., a leading South Korean vaccine and biotech company, announced on Monday that its phase 3 clinical trial plan for a heterogeneous ...
Mar 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion ex-Chairman Seo set to return to management; group stocks rally
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion teams up with bio venture to develop new anti-cancer drug
South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's EuBiologics to receive support from Gates Foundation
South Korea's biopharmaceutical company EuBiologics Co. announced on Wednesday that its meningococcal pentavalent conjugate vaccine EuMCV5 under dev...
Feb 23, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine
South Korea's GC Biopharma Corp. is set to regain the No. 1 spot in global production of chickenpox vaccines after earning qualification to enter th...
Feb 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Feb 20, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Truxima shows safety, efficacy in post-marketing study
South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma's Ochang facility gets WHO PQ certification
GC Biopharma Co.'s production facility in Ochang (North Chungcheong Province) secured a pre-qualification (PQ) certification from the World Health O...
Feb 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Red ginseng prevents flu, pneumonia: research
Studies have shown that South Korea's hongsam (red ginseng) is effective in preventing respiratory diseases such as the flu and pneumonia.The Korean...
Feb 08, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience's SKYCellflu approved by Chilean health authority
SK Bioscience Co., a bio and pharmaceutical affiliate of South Korea's SK Group, announced on Thursday that its world-first cell culture-based quadr...
Feb 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Jan 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...
Jan 11, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience's shingles vaccine obtains product approval from Malaysia
SK Bioscience Co. said on Monday that its shingles vaccine Sky Zoster has been given approval by Malaysia's National Pharmaceutical Regulatory Age...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
HLB Therapeutics signs contract for COVID vaccine distribution rights
South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention ...
Dec 20, 2022 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma confirms safety of flu vaccine in phase 1 trial
South Korea's leading pharmaceutical company GC Biopharma Corp. said on Thursday that it has confirmed the safety and immunogenicity of the patch-ty...
Dec 15, 2022 (Gmt+09:00)
-
Artificial intelligence
LG Group think tank unveils breakthrough AI tech Exaone
LG AI Research, the artificial intelligence (AI) think tank of South Korea's LG Group, on Thursday unveiled Exaone, a gigantic AI technology that ra...
Dec 09, 2022 (Gmt+09:00)
Latest News
- 1 Google to invest $100 mn in Gentle Monster in smart glasses push
- 2 Growth equity portfolio largely shielded from policy headwinds: Summit
- 3 Naver Financial seeks to acquire S. Korean real estate data platform Asil
- 4 KakaoBank shares surge on Thai virtual bank approval
- 5 Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma